ALDX Stock Risk & Deep Value Analysis
Aldeyra Therapeutics Inc
DVR Score
out of 10
What You Need to Know About ALDX Stock
We analyzed Aldeyra Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ALDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ALDX Risk Analysis & Red Flags
What Could Go Wrong
The company could face devastating financial penalties from class-action lawsuits, leading to insolvency or massive shareholder dilution. Simultaneously, the repeated FDA rejections of its primary drug for dry eye disease eliminate its most significant market opportunity, leaving it with no clear path to substantial revenue and further exacerbating cash runway concerns.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Third FDA Complete Response Letter for reproxalap in dry eye disease on 2026-03-17
- ⚠
Multiple class-action lawsuits alleging securities fraud and misleading statements
- ⚠
Chief Development Officer's resignation by March 2026 amidst crisis
- ⚠
Significant institutional ownership decline of 6.62% in Q ending March 2026
- ⚠
Analyst downgrade and severe price target reduction post-CRL (HC Wainwright: $10 to $2)
Upcoming Risk Events
- 📅
Adverse rulings or settlements in class-action lawsuits (Ongoing)
- 📅
Further deterioration of cash runway and need for highly dilutive financing
- 📅
Clinical trial failures for any remaining pipeline assets
- 📅
Delisting from stock exchange due to prolonged low share price or non-compliance
When to Reconsider
- 🚪
Any adverse court ruling or settlement in the class-action lawsuits
- 🚪
Announcements of highly dilutive equity raises without a clear path to profitability
- 🚪
Cash balance falling below 12 months of operating expenses without new funding
Unlock ALDX Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
The previous investment thesis for 10x growth based on reproxalap in dry eye disease has been fundamentally invalidated by the third FDA CRL and subsequent securities fraud lawsuits. The company now faces severe existential and financial risks, making any investment highly speculative and unsuitable for growth-oriented portfolios within the 3-5 year timeframe. A 10x return is now virtually impossible under current conditions.
Is ALDX Stock Undervalued?
Unlock the full AI analysis for ALDX
Get the complete DVR score, risk analysis, and more
ALDX Price Targets & Strategy
12-Month Target
$2.00
Bull Case
$5.00
Bear Case
$0.50
Valuation Basis
Based on HC Wainwright's post-CRL price target, reflecting a highly distressed valuation for remaining assets and allergic conjunctivitis market.
Entry Strategy
Avoid investment given extreme uncertainty and legal risks. For aggressive, highly speculative investors, consider only after clarity on lawsuits and a stable cash position, potentially near 52-week lows if any fundamental change occurs.
Exit Strategy
Current holders should consider exiting to mitigate further losses. For new positions, a stop loss below recent lows ($1.20) or if cash runway concerns heighten.
Portfolio Allocation
0% for all risk tolerances given the current existential risks and lack of 10x growth pathway.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ALDX Financially Healthy?
Valuation
P/E Ratio
-3.18
Price/Book
1.71
Profitability
Return on Equity
-65.19%
EPS
$-0.97
Balance Sheet
Current Ratio
6.49
Quick Ratio
6.36
Debt/Equity
0.24
Total Debt
$15.57M
Cash & Equivalents
$90.06M
Cash Flow
Operating Cash Flow
-$45.71M
Free Cash Flow
-$45.71M
EBITDA
-$60.90M
Other
Beta (Volatility)
0.97
Does ALDX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
The company's intellectual property for reproxalap in dry eye disease has proven insufficient to overcome regulatory hurdles after three attempts, essentially eroding any potential competitive advantage in that market. Other pipeline assets are not sufficiently advanced or differentiated to create a durable moat.
Moat Erosion Risks
- •Inability to overcome regulatory challenges for lead candidates
- •Intense competition from well-capitalized pharmaceutical companies
- •Loss of key talent and scientific expertise due to ongoing crises
ALDX Competitive Moat Analysis
Sign up to see competitive advantages
ALDX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Heavily negative post-FDA CRL and lawsuit announcements, significant price drop)
Institutional Sentiment
Negative (Reflected in institutional selling and analyst downgrades)
Insider Activity (Form 4)
Director Richard Douglas bought 70,000 shares ($98,000) on 2026-03-19. Director Michael Alfieri bought 5,000 shares at ~$1.42/share on 2026-03-18. These small buys are overshadowed by the overwhelming negative news.
Options Flow
Normal options activity (No specific data indicating unusual institutional options positioning.)
Earnings Intelligence
Next Earnings
Estimated early-May 2026
Surprise Probability
Low (Focus will be on cash burn and pipeline updates rather than revenue/EPS beats)
Historical Earnings Pattern
Historical earnings reaction patterns are not available from the provided data. However, given the recent news, any earnings report is likely to be highly volatile.
Key Metrics to Watch
Competitive Position
Top Competitor
AbbVie (Xiidra)
Market Share Trend
Losing (Failed to gain entry into the major dry eye market, effectively ceding ground to established players).
Valuation vs Peers
Not meaningfully comparable; Aldeyra lacks significant approved product revenue and faces existential risks, trading at distressed valuations while peers are profitable with established market share.
Competitive Advantages
- •None apparent for the key dry eye market opportunity (reproxalap's efficacy issues and repeated FDA rejections erode any potential IP advantage there).
- •Potential for reproxalap in allergic conjunctivitis (a smaller market, but approved).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ALDX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (Estimated early-May 2026)
- •Updates/clarity on class-action lawsuits (Ongoing)
Medium-Term (6-18 months)
- •Potential for new clinical trial data for other pipeline assets (unspecified)
- •Strategic partnership or out-licensing deal for reproxalap (allergic conjunctivitis indication, highly uncertain)
Long-Term (18+ months)
- •Complete overhaul of drug development strategy (requires new leadership and funding)
- •Discovery of a new blockbuster drug (highly speculative and outside 3-5 year window)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ALDX?
- ✓
A clear resolution of the class-action lawsuits without crippling financial penalties
- ✓
Positive clinical data for an entirely new, high-potential pipeline asset with a clear regulatory path
- ✓
Significant and unexpected M&A interest or a substantial non-dilutive financing event
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Aldeyra Therapeutics Inc (ALDX)?
As of March 25, 2026, Aldeyra Therapeutics Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Aldeyra Therapeutics Inc?
Aldeyra Therapeutics Inc's market capitalization is approximately $108.9M..
What is the risk level for ALDX stock?
Our analysis rates Aldeyra Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ALDX?
Aldeyra Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -3.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Aldeyra Therapeutics Inc's revenue growing?
Aldeyra Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ALDX stock profitable?
Aldeyra Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ALDX DVR analysis updated?
Our AI-powered analysis of Aldeyra Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ALDX (Aldeyra Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.